Cited by 98Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchMemory and Neural Mechanisms

Accelerated aging of the GABAergic septohippocampal pathway and decreased hippocampal rhythms in a mouse model of Alzheimer's disease

Open access
Rubio, Sara E., Vega‐Flores, Germán, Martínez, Albert, Bosch, Carles, Pérez‐Mediavilla, Alberto, Río, Joaquín del, Gruart, Agnès, Delgado‐García, José María +2 more·2012·The FASEB Journal

Abstract

Patients with Alzheimer's disease (AD) display altered functioning of cortical networks, including altered patterns of synchronous activity and a serious deficit in cholinergic septohippocampal (SH) innervation. However, the mechanisms underlying these alterations and the implication of the GABAergic SH component in AD are largely unknown. In addition, the GABAergic septohippocampal pathway (SHP) is believed to regulate synchronous hippocampal activity by controlling the activity of interneurons. Here we show, using well‐characterized pathway tracing experiments, that innervation of the GABAergic SHP decreases during normal aging. Furthermore, in an AD mouse model (hAPP Sw,Ind ; J20 mice), the GABAergic SHP shows a dramatic and early onset of this decrease in 8‐mo‐old mice. This decline is not caused by neuronal loss, but by the reduced number and complexity of GABAergic SH axon terminals. Finally, we demonstrate that hippocampal θ and γ rhythm power spectra are markedly diminished in 8‐mo‐old behaving mice expressing mutated hAPP. In addition to the well‐known loss of cholinergic input to the hippocampus in AD, these data suggest that the altered patterns of synchronous activity seen in patients with AD could be caused by the loss of GABAergic SH axons, which modulate hippocampal network activities.—Rubio, S. E., Vega‐Flores, G., Martínez, A., Bosch, C., Pérez‐Mediavilla, A., del Río, J., Gruart, A., Delgado‐García, J. M., Soriano, E., Pascual, M. Accelerated aging of the GABAergic septohippocampal pathway and decreased hippocampal rhythms in a mouse model of Alzheimer's disease. FASEB J. 26, 4458–4467 (2012). www.fasebj.org

Integrity signals

Registry

Crossref · 10.1096/fj.12-208413

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Transgenic mice with AD-like pathology have reduced gamma power, and in one model this reduction precedes cognitive impairment and amyloid plaque formation.

    “Transgenic mice with AD-like pathology were found to have reduced gamma power that, in one model, precedes cognitive impairment and amyloid plaque formation [21,22].”

    From Parvalbumin interneuron vulnerability and brain disorders (2021) · cites this paper as [22]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rubio, S. E., Vega‐Flores, G., Martínez, A., Bosch, C., Pérez‐Mediavilla, A., Río, J. D., Gruart, A., Delgado‐García, J. M., Soriano, E., & Pascual, M.
Affiliations
  • Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
  • Universidad Pablo de Olavide (ES)
  • Developmental Neurobiology and Regeneration Laboratory Institute for Research in Biomedicine Barcelona Spain
  • Centro de Investigación Biomédica en Red para Enfermedades Neurodegenerativas Madrid Spain
  • Division of Neurosciences Pablo de Olavide University Seville Spain
Corresponding author
Pascual, Marta
Venue
The FASEB Journal
Publisher
Wiley
Published
2012-07-26
Volume
26
Issue
11
Pages
4458-4467
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W2144901851
Cited by
98
References
60
Citations by year
2026: 5 · 2025: 7 · 2024: 6 · 2023: 7 · 2022: 5 · 2021: 9 · 2020: 13 · 2019: 6 · 2018: 6 · 2017: 6 · 2016: 11 · 2015: 3 · 2014: 5 · 2013: 8 · 2012: 1
FWCI
3.65
Type
journal article
Language
en
Open access
Locations
  • The FASEB Journal (publishedVersion)
  • PubMed (publishedVersion)
  • Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
Funders
  • Institute for Research in Biomedicine
  • Ministry of Science and Innovation, New Zealand (BFU2008‐3980)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
Keywords
Alzheimer's disease, theta oscillations, gamma oscillations, normal aging, interneurons, cholinergic innervation, mouse model
MeSH terms
Aging, Alzheimer Disease, Animals, Disease Models, Animal, Hippocampus, Male, Mice, Inbred C57BL, Mice, Neurologic Mutants, Mice, Transgenic, Septal Nuclei, Theta Rhythm, Amyloid beta-Protein Precursor, Mice, GABAergic Neurons

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review